Moderna, Inc.

Nasdaq:MRNA

Biological Products, (No Diagnostic Substances)·CAMBRIDGE, MA

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines.

CEO

Bancel Stephane

CFO

Mock James M

Financials

20 shown

Type	Period	Ended	Filed
10-K	FY 2025	12/31/25	2/20/26	→
10-Q	Q3 2025	9/30/25	11/6/25	→
10-Q	Q2 2025	6/30/25	8/1/25	→
10-Q	Q1 2025	3/31/25	5/1/25	→
10-K	FY 2024	12/31/24	2/21/25	→
10-Q	Q3 2024	9/30/24	11/7/24	→
↓

Earnings Releases (8-K)

27 shown

Filed	Period
2/13/26	Q1 FY2026	→
1/12/26	Q4 FY2026	→
11/6/25	Q4 FY2025	→
8/1/25	Q3 FY2025	→
5/1/25	Q2 FY2025	→
2/14/25	Q1 FY2025	→
↓

News (8-K)

31 shown

Filed	Type	Description
3/5/26	Agreement	Entry into a Material Definitive Agreement	→
2/11/26	Reg FD	Regulation FD Disclosure	→
1/5/26	Reg FD	Regulation FD Disclosure	→
11/24/25	Agreement	Entry into a Material Definitive Agreement	→
11/20/25	Reg FD	Regulation FD Disclosure	→
11/13/25	Vote	Submission of Matters to a Vote of Security Holders	→
↓

Prospectuses & Registrations

7 shown

Filed	Form	Description
2/20/26	S-8	S-8	→
3/11/25	ARS	ANNUAL REPORT TO SECURITY HOLDERS	→
2/21/25	S-8	S-8	→
3/15/24	ARS	MODERNA, INC. - ARS	→
2/23/24	S-8	S-8	→
5/5/23	S-3ASR	S-3ASR	→
↓

Filing History(1001 filings)

TypeDateAccessionPeriodSize

Mar 6, 2026

0001682852-26-000051PRIMARY DOCUMENT

Mar 5, 2026

8.4 KB

Mar 6, 2026

0001682852-26-000049PRIMARY DOCUMENT

Mar 5, 2026

8.3 KB

8-K

Mar 5, 2026

0001682852-26-0000478-K

Mar 3, 2026

149.1 KB

Mar 3, 2026

0001682852-26-000044PRIMARY DOCUMENT

Mar 1, 2026

8.1 KB

Mar 3, 2026

0001682852-26-000042PRIMARY DOCUMENT

Feb 27, 2026

30.0 KB

Mar 3, 2026

0001682852-26-000040PRIMARY DOCUMENT

Feb 27, 2026

33.4 KB

Mar 3, 2026

0001682852-26-000038PRIMARY DOCUMENT

Feb 27, 2026

23.0 KB

144

Mar 2, 2026

0001959173-26-001610

—

4.3 KB

Feb 25, 2026

0001682852-26-000036PRIMARY DOCUMENT

Feb 23, 2026

13.4 KB

144

Feb 23, 2026

0001959173-26-001320

—

4.3 KB

S-8

Feb 20, 2026

0001682852-26-000034S-8

—

197.8 KB

10-K

Feb 20, 2026

0001682852-26-00003310-K

Dec 31, 2025

15.0 MB

Feb 13, 2026

0001682852-26-000024PRIMARY DOCUMENT

Feb 11, 2026

6.1 KB

Feb 13, 2026

0001682852-26-000021PRIMARY DOCUMENT

Feb 11, 2026

6.1 KB

Feb 13, 2026

0001682852-26-000019PRIMARY DOCUMENT

Feb 11, 2026

8.0 KB

Feb 13, 2026

0001682852-26-000017PRIMARY DOCUMENT

Feb 11, 2026

8.4 KB

8-K

Feb 13, 2026

0001682852-26-0000158-K

Feb 13, 2026

318.3 KB

8-K

Feb 11, 2026

0001682852-26-0000128-K

Feb 3, 2026

170.2 KB

SCHEDULE 13G/A

Feb 9, 2026

0001088875-26-000008

—

7.4 KB

SCHEDULE 13G/A

Feb 6, 2026

0000315066-26-000599

—

11.3 KB

SCHEDULE 13G

Feb 5, 2026

0000315066-26-000495

—

11.1 KB

8-K

Jan 12, 2026

0001682852-26-0000078-K

Jan 12, 2026

175.4 KB

Jan 6, 2026

0001682852-26-000005PRIMARY DOCUMENT

Jan 5, 2026

8.3 KB

8-K

Jan 5, 2026

0001682852-26-0000038-K

Jan 5, 2026

233.0 KB

SC TO-I/A

Dec 16, 2025

0001682852-25-000098SC TO-I/A

—

25.0 KB

25 filings shown

Filed	Form	Description
10/20/25	DEFA14A	DEFA14A	→
10/15/25	DEF 14A	DEF 14A	→
10/3/25	PRE 14A	OTHER PRELIMINARY PROXY STATEMENTS	→
3/11/25	DEFA14A	DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS	→
3/11/25	DEF 14A	DEFINITIVE PROXY STATEMENT	→
3/21/24	DEFA14A	MODERNA, INC. - DEFA14A	→
↓

Moderna, Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(1001 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
3/6/26	4	PRIMARY DOCUMENT	→
3/6/26	4	PRIMARY DOCUMENT	→
3/3/26	4	PRIMARY DOCUMENT	→
3/3/26	4	PRIMARY DOCUMENT	→
3/3/26	4	PRIMARY DOCUMENT	→
3/3/26	4	PRIMARY DOCUMENT	→
↓

Filed	Form	Description
3/2/26	144	144	→
2/23/26	144	144	→
2/9/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
2/6/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
2/5/26	SCHEDULE 13G	SCHEDULE 13G	→
12/16/25	SC TO-I/A	SC TO-I/A	→
↓